Fonte: Il Messaggero
The Italian Company Advent will produce the first 1000 doses
The vaccine for the novel coronavirus is going to be manufactured in Pomezia, Italy. ADVENT Srl., the GMP-certified Contract Development and Manufacturing Organization of IRBM Group, and Jenner Institute of the Oxford University have already started the procedures for the clinical trials.
The Jenner Institute produced a vaccine against MERS with remarkable success, and is going to use the same technology for the novel coronavirus. The vaccine is produced thanks to a safe version of an adenovirus. The adenovirus has been modified so that it cannot reproduce within the body, but it is able to trigger a process that stops the coronavirus from causing an infection.
Dr. Piero Di Lorenzo, President and CEO of IRBM, CEO of Advent and CNCCS, expresses his enthusiasm:
“We are thrilled to be working with the Jenner Institute on this critical project […].Once again IRBM Group is at the forefront of R&D […]”
Article by Massimiliano Gobbi published on Il Tempo – 09/02/2020